MINIject (MIGS)

MINIjectTM is designed to significantly reduce IOP by enhancing aqueous humour outflow from the anterior chamber to the suprachoroidal space. Implantation is swift and predictable using a trigger in a single-step procedure.

MIGS implant
MINIject implanted in suprachoroidal space

MINIject exhibits all the advantages of the STAR® material such that it conforms to the eye anatomy, and benefits from sustained drainage efficacy over time due to bio-integration of surrounding tissues into the material. A natural flow speed results, which reduces the incidence of fibrosis, minimises scarring, and increases implant durability.

The MINIject first-in-human clinical trial showed that the implantation of MINIject resulted in an average 39% IOP reduction to a mean of 14.2 mmHg at six months. In addition, 87.5% of patients were able to discontinue topical medication usage and remained medication-free at six months. There were no serious ocular adverse events.